Trial Profile
A Human Physiologic Study to Evaluate the Renal and Neurohumoral Effects of a Novel Chimeric Natriuretic Peptide, CD-NP, in Subjects With Stable Chronic Heart Failure.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Cenderitide (Primary)
- Indications Chronic heart failure
- Focus Pharmacodynamics
- 02 May 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 02 May 2011 Status changed from completed to recruiting as reported by ClinicalTrials.gov.
- 07 May 2010 Planned end date changed from Jul 2010 to Dec 2010 as reported by ClinicalTrials.gov.